Areteia Therapeutics

Closed

Committed to putting asthma patients in better control

Chapel Hill, United States · Founded 2022 · $425.0M raised

Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$425.0M
Last Round
$75.0M Series AFeb 2024
Rounds
2

About

Areteia Therapeutics was a clinical-stage biotechnology company developing dexpramipexole, an oral eosinophil-maturation inhibitor, to treat eosinophilic asthma and put patients back in control of their disease. Focused on novel inflammation and immunology therapies, it raised $425M in funding led by ARCH Venture Partners and GV. The company wound down operations in late 2025 amid Phase 3 drug trials.

Summary

Areteia Therapeutics is a Biotech company based in Chapel Hill, United States, founded in 2022. It has raised $425.0M in total across 2 rounds, most recently a $75.0M Series A round in Feb 2024.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series ASeries A ExtensionFeb 2024
$75.0M

Sign up to see all 2 rounds

Series A — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Areteia Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/areteia-therapeutics"><img src="https://indexed.vc/api/badge/company/areteia-therapeutics" alt="Areteia Therapeutics on Indexed.vc" width="260" height="76" /></a>